Sign In
Buy STAA
$28.26
-0.230 (-0.81%)
At Close: Jun 03, 2026
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Com
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, t
Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
07:00am, Tuesday, 16'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on a report published by Institutional Shareholder Services Inc. (“ISS”), an in
Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
06:35pm, Monday, 15'th Dec 2025
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision
Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
08:40am, Friday, 12'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advis
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
09:47am, Thursday, 11'th Dec 2025
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, t
Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
07:00am, Thursday, 11'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today reacted to the proxy statement supplement filed by STAAR S
STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process
12:53pm, Wednesday, 10'th Dec 2025
Yunqi Capital Limited, which holds a 5.1% stake in STAAR Surgical Company (NASDAQ: STAA), issued a letter to shareholders on Wednesday.
Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer
07:05am, Wednesday, 10'th Dec 2025
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Com
What Makes Staar Surgical (STAA) a New Buy Stock
01:01pm, Tuesday, 09'th Dec 2025
Staar Surgical (STAA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical
12:39pm, Tuesday, 09'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today responded to the amended transaction terms of the proposed
Alcon Announces Amended Merger Agreement with STAAR Surgical
08:30am, Tuesday, 09'th Dec 2025
GENEVA--(BUSINESS WIRE)--Alcon Announces Amended Merger Agreement with STAAR Surgical.
Broadwood Partners Reiterates Opposition to STAAR Surgical's Sale to Alcon Following Conclusion of Performative Go-Shop Process
01:28pm, Monday, 08'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us,” or “our”) today issued the following open letter to the shareholders of S
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that leading proxy advisory firm Egan-Jones Ratings Company (“Egan-Jones”) ha
STAAR Surgical Announces Expiration of Go-Shop Period
08:00am, Monday, 08'th Dec 2025
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, t
